Summary

29"
Anti-tuberculosis (TB) drugs while being highly potent in vitro require prolonged 30" treatment to control Mycobacterium tuberculosis (Mtb) infections in vivo. We report 31"
here, mesenchymal stem cells (MSCs) shelter Mtb to help tolerate anti-TB drugs.
32"
MSCs uptake Mtb readily and allow them grow unabated despite having functional 33" innate pathway of phagosome maturation. Unlike macrophage-resident ones, MSC-34"
resident Mtb tolerates anti-TB drugs remarkably well, a phenomenon requiring 35" proteins ABCC1, ABCG2 and vacuolar-type H + ATPases. Additionally, contrary to 36" what is classically known, IFNγ and TNFα aid mycobacterial growth within MSCs.
37"
Mechanistically, evading drugs and inflammatory cytokines by MSC-resident Mtb is 38" dependent on elevated PGE2 signaling, which we subsequently verified in vivo 39"
analyzing sorted CD45 -CD73 + SCA1 + -MSCs from the lungs of infected mice.
40"
Moreover granulomas from human pulmonary and extra-pulmonary TB show 41"
Introduction
45"
Mycobacterium tuberculosis (Mtb) continues to infect, cause illness (tuberculosis) and 46" kill large number of individuals globally. Among numerous factors that thwart any 47" tuberculosis control program, lack of an effective vaccine and long duration of 48" treatment are the two most critical ones 1, 2 . Long treatment duration is majorly 49" attributed behind non-compliance and emergence of drug-resistant tuberculosis 50"
including multi-and extensively drug-resistant (MDR and XDRs respectively) ones 1 .
51"
While standard-of-care anti-TB drugs are very efficient in killing Mtb in liquid culture 52" and during ex vivo infection studies in macrophages, their efficacy is dramatically 53" compromised during in vivo infection studies and in the clinical practices, requiring 54" prolonged treatment duration 3 . It is believed that Mtb undergoes metabolic 55" adaptations within host granulomas, which render these bacteria less vulnerable to the 56" standard drugs 4, 5 . Driving factors, which cause such adaptations include nitric oxide 57" (NO), redox stress (ROS), low oxygen (hypoxia), low nutrients or altered carbon 58" source 4,6-11 .
59"
Curiously, whatever we know about the intracellular lifestyle of mycobacteria in the 60"
hosts is mostly through studies on macrophages 12, 13 . Are there additional niches of 61" mycobacteria in vivo, which could facilitate the perceived metabolic adaptations?
62"
While there is no clear answer to the above assumption, there are certainly different 63" other cell types which get infected inside the host including lung epithelial cells, 64" macrophages, neutrophils, dendritic cells, adipocytes and mesenchymal stem cells 65" (MSCs) [14] [15] [16] [17] [18] . MSCs are peculiar among these cells since they were first reported to 66" dampen the host immunity against tuberculosis around the granulomas 19 .
67"
Subsequently it was observed that these cells are the site of persistent or latent 68" bacterial infection 20 . Interestingly, latent bacteria are perceived to be more tolerant to 69" anti-TB drugs [21] [22] [23] . Moreover, MSCs are classically known for their immune-70" modulatory functions [24] [25] [26] . Whether MSCs provide a privileged niche to mycobacteria 71" allowing them to withstand drug and evade host immunity remains unclear. Potential 72" benefits mycobacteria enjoys within these cells continue to remain obscure due to 73" lack of systematic studies on the intracellular lifestyle of Mtb within MSCs. In this 74" study, using adipose tissue-derived mesenchymal stem cells (ADSCs), we show that 75"
Mtb not only escapes the effect of anti-TB drugs while residing within ADSCs but 76" also effectively evade host immune mediators. We further establish the mechanism 77" behind these unusual properties of ADSCs and show their relevance during in vivo 78" infection in mice as well as studies on the human subjects. 79" (RAB7), lysosomes (LAMP1) and acidified lysosomes (LAMP1 and LysoTracker).
204"
At any given time post-infection, a large number of bacteria (~40-50%) stayed within 205" RAB5 positive early phagosomes inside the ADSCs (Fig. S3A ). While only 2-5% 206"
bacteria were ever present in RAB7 positive late phagosomes (Fig. S3B) . Similar 207" distribution of Mtb is also reported within macrophages as reported by others and also 208" confirmed by us 36 (Fig. S3C ). This reflects the phagosome maturation arrest inflicted 209"
by Mtb in the infected macrophages 36, 37 . However unlike macrophages where 210" LAMP1-Mtb or Lysotracker-Mtb co-localization rarely crosses ~15% 27 , there are 211" more bacteria (~30-40%) present in LAMP1 or Lysotracker-LAMP1 double positive 212" compartments in ADSCs (Fig. 2I-J, S3D ). The matured lysosomes, i.e. LAMP1 213" positive acidified compartments indeed reflect the killing mechanism in ADSCs since 214"~8 0% of intracellular BCG, the strain that gets killed within ADSCs, are present in 215"
Lysotracker-LAMP1 double positive compartments (Fig. 2K) . Interestingly, treatment 216" with IFNγ, TNFα or MK571 in general led to a decline in bacterial localization to 217" LysoTracker or LAMP1+LysoTracker compartments however LAMP1 compartment 218" alone showed only marginal decline (Fig. 2J, S3D ). Exclusion of Cathepsin D, the 219" lysosomal protease, from LAMP1-Lysotracker positive compartment strongly 220" correlated with increased bacterial survival upon IFNγ or MK571 treated cells (Fig.  221" 2L, S3D). Interestingly, ABCC1 and ABCG2 were also found to co-localize with Mtb 222"
suggesting their recruitment to phagosomes (Fig. S3E) . At least in case of TNFα 223" treatment, exclusion of ABCC1 from the LAMP1-LysoTracker compartment was 224" highly significant whereas IFNγ or MK571 treatment showed only marginal decline 225" (Fig. 2M ) leaving an impression that ABCC1 is probably directly involved in 226" bacterial killing. However their direct role in Mtb killing is supported by only one set 227" of evidences-increased bacterial survival upon their knockdown or inhibition. The 228" strong correlation between bacterial killing and their co-localization to LAMP1-229"
Lysotracker-CatD compartment nonetheless suggest active role of classic phagosome 230" maturation pathways in bacterial killing with ADSCs.
231"
Interestingly, in contrast to what is known in macrophages 27 , Mtb very rarely co-232" localized to autophagosomes and xenophagy flux was completely absent in ADSCs 233" (Fig S4A) , suggesting little role if any, of autophagy in controlling Mtb within 234"
ADSCs. Curiously, ADSCs showed very high basal autophagy flux (Fig. S4B) , which 235" presumably is critical for maintaining the stem cell like property of these cells, 236"
highlighting the segregation of homeostatic and anti-bacterial arms of autophagy as 237"
reported by us earlier 38 . Moreover treatment with IFNγ led to increased autophagy 238" flux in ADSCs, unlike what was reported previously for macrophages (Fig. S4C ) 39 .
239"
Unlike macrophages, IFNγ treatment had no effect on cellular ROS generation in 240" ADSCs ( Fig. S4D) . To some extent, this could explain why IFNγ failed to induce 241" killing of Mtb within ADSCs. however in all such known cases, MSCs execute its role by modulating functions of 251" other cells, including T cells and macrophages [40] [41] [42] . Some of the key mediators that 252"
help MSCs execute these functions are PGE2, IDO1, IL6, CCL2, VEGFC, LIF etc. 253" 24, [42] [43] [44] [45] [46] . In our microarray data, genes from the PGE pathway like PTGS2, PTGES and 254" PTGR2 showed nearly 8, 4 and 4 folds (log 2 ) increase in expression respectively (Fig. 255" S5A) . Similarly IDO1 showed 6 folds increase, whereas LIF, IL6, CCL2 and VEGF 256" each showed more than 3 fold increase in expression post-infection (Fig. S5A) . We 257" first tested PGE2 levels in the culture supernatants of ADSCs that were infected with 258"
H37Rv. Consistent with the microarray data PGE2 ELISA confirmed increased 259" synthesis and secretion of PGE2 from Mtb-infected ADSCs (Fig. 3A) . Interestingly, 260" treatment with IFNγ or TNFα further increased PGE2 levels in the culture 261" supernatants whereas MK571 treated cells showed almost similar level of PGE2 as 262" infected control cells (Fig. 3A) . We used celecoxib, a widely used PTGS2 (or COX2) 263" inhibitor, which is also an FDA approved drug in the market, as a negative control.
264"
Mtb-infected ADSCs treated with celecoxib showed negligible PGE2 levels by 265" ELISA ( Fig. 3A) . Next we treated Mtb-infected ADSCs with celecoxib at 50, 150 and 266" 250µM concentrations under all the conditions tested so far in this study. Treatment 267"
with celecoxib reduced Mtb CFU in a dose dependent manner across the conditions 268" including infection alone or when treated with IFNγ, TNFα or MK571 (Fig. 3B) .
269"
Similar results were also obtained with EP2 receptor (receptor for PGE2) antagonist 270" PF04418948, suggesting involvement of signaling through PGE2 pathway in bacterial 271" survival ( Fig. S5B) . Celecoxib was also effective in killing Mtb within macrophages 272"
however not as dramatically as observed in MSCs (Fig. S5C ). Unlike ADSCs, there 273" was no increase in PGE2 release by THP-1 macrophages upon infection or treatment 274"
with IFNγ or TNFα (Fig. S5D ). We also verified these results by knocking down 275" PTGS2 (COX2) using specific siRNAs ( Fig. 3C and S5E ). Confocal microscopy 276"
revealed that majority of bacteria in celecoxib treated cells or PF04418948 treated 277" cells or COX2 siRNA treated cells co-localized with LAMP-1, Lysotracker as well as 278" CatD ( Fig. 3D and S5F ). Interestingly, COX2 inhibition by celecoxib also helped 279" limit the drug tolerant phenotype in ADSCs against INH, irrespective of treatment 280"
with IFNγ or TNFα (Fig. 3E ). Moreover, MK571, which itself decreases drug-tolerant 281"
Mtb in ADSCs when combined with celecoxib treatment further decreases the drug-282" tolerant population of Mtb within ADSCs (Fig 3E) . The effect of celecoxib on 283"
bacterial drug tolerance was PGE2-mediated and not due to possible role of certain 284" COX2 inhibitors directly on bacterial drug-resistance protein MDR1 47 since 285" knocking down COX-2 also led to a remarkable decline in INH-tolerant as well as 286" rifampicin-tolerant Mtb population within ADSCs ( Fig. 3F and 3G respectively).
287"
Efficacy of COX2 knockdown by siRNA on bacterial drug tolerance also rule out role 288" of PGE2 inhibitors in directly regulating the efflux proteins as reported previously 48 .
289"
MSCs serve as a niche for Mtb during in vivo infection allowing drug tolerance in 290"
PGE2 dependent manner 291"
While all the results so far were performed on human primary adipose tissue-derived 292" mesenchymal stem cells, we next wanted to explore whether these cells actually get 293" involved during in vivo infection in mice and humans as well as to know whether 294" PGE2 signaling plays similar role in vivo. We infected C57BL/6 mice with H37Rv 295" through aerosol challenge and 4 weeks post-infection, these animals were divided into 296" four groups: control, celecoxib (50mg/kg), INH (10mg/kg) or INH+celecoxib; and 297" treated for subsequent 4 and 8 weeks. From the initial bacterial load of 100-150 per 298" animal, it reached around 10 6 per animal by end of 4 weeks, 2x10 6 by the end of eight 299" weeks and 3x10
6 by the end of 12 weeks in the lungs ( Fig 4A) . While celecoxib 300" treatment alone significantly reduced bacterial CFU after 4 weeks of treatment, the 301" effects were not visible at 8 weeks post-treatment (Fig. 4A ). INH treatment brought 302" the bacterial CFU significantly down at both 4 and 8 weeks post-treatment (Fig. 4A) .
303"
Animals, which received both celecoxib and INH showed more significant reduction 304" in bacterial CFU in the lungs at both 4 and 8 weeks post-treatment (Fig. 4A ). Similar 305" results were also obtained in the spleen (Fig. 4B ). The combination treatment was 306" significantly more effective with respect to INH or celecoxib alone in controlling 307" bacterial load in spleen at 12 weeks (Fig. 4B) .
308"
We next sorted lung tissues from the infected animals at each time points and 309" treatment groups into CD45 -CD73 + Sca1 + (MSCs) and CD45 + CD11B + Ly6G
-310"
(macrophages) cells with a purity of more than 90% ( Fig. 4C and S5G ). Population of 311" macrophages increased dramatically from week 4 to week 8, across all treatment 312" groups and declined subsequently at 12 weeks (Fig. 4D) . Population of MSCs was 313"
highest at 4 weeks post-infection, which declined rapidly at 8 and 12 weeks post-314" infection ( Fig. 2E ). Lysing and plating these sorted cells on 7H11 media showed 315" presence of Mtb in both macrophages and MSCs (Fig. 4F-G) . Number of bacilli in 316" both cells progressively increased from week 4 to week 12, shown as number of 317" bacilli per ten thousand cells ( Fig. 4F and 4G ). The macrophage-resident Mtb were 318" not affected by celecoxib, INH or both at 4 weeks post-treatment, largely due to low 319" dose of INH used in this study. Moreover, in vivo macrophages are also expected to 320" have activated phenotype, thereby could develop drug tolerance as reported 321" previously 35 . At 8 weeks post-treatment, each of these treatments resulted in 322" significant decline in macrophage-resident Mtb population (Fig. 4F) . Interestingly, 323" MSC-resident Mtb could be killed by INH or celecoxib alone or in combination even 324" at 4 weeks post-treatment (Fig. 4G) . However, consistent with the ex vivo results, 325" effect of INH alone on MSC-resident Mtb was relatively less in magnitude with 326" respect to celecoxib alone or celecoxib+INH treated animals ( Fig. 4G) . At 8 weeks of 327" treatment, INH and celecoxib were equally effective on MSC-resident Mtb, while the 328" combined treatment resulted in additive effect and showed further decline in Mtb 329" CFU ( Fig. 4G) .
330"
MSCs are present in human pulmonary and extra-pulmonary tuberculosis 331" granulomas
332"
The results so far establish that MSCs serve as a niche for Mtb providing drug and 333" immune privileged niche, in PGE2 dependent manner both ex vivo and in vivo in 334"
animals. We next analyzed presence and spatial localization of CD73 + cells with 335" respect to Mtb in tissue sections from pulmonary and extra-pulmonary TB lesions 336" from human subjects. CD73 + cells were found across different pulmonary and extra-337" pulmonary tuberculosis lesions like gut and lymph nodes ( Fig. 4H-I ). Intestinal biopsy 338" samples were taken from granuloma-positive confirmed intestinal tuberculosis 339" patients 49 . In lung and lymph node biopsies where in addition to CD73, Ag85B of 340"
Mtb was also stained, presence of these cells in the close vicinity of Mtb was apparent 341" (Fig. 4I) .
342"
Discussions
343"
Almost everything that we know about the intracellular lifestyle of Mtb largely 344" emerged through studies on monocyte/macrophage models. The host responses and 345" mechanism of immune evasions are also studied keeping in mind macrophages as the 346" primary cells where the bacteria reside 12, 13 . The present study was undertaken to 347" understand how mesenchymal stem cells (MSCs) questioned whether these efflux proteins could also help throwing out anti-TB drugs, 365" thereby helping in drug-tolerance. Our results indeed show increased expression and 366" involvement of ABCC1 and ABCG2, in drug tolerance, both of which acted 367" independently since their combined effects were greater than individual effects.
368"
However, inhibition of vacuolar-type H + ATPase by BafA1 led to a more dramatic 369" decline in drug-tolerant population, suggesting phago-lysosomal environment to be 370" the key factor behind drug-tolerance. Moreover, increase in bacterial CFU upon 371" ABCC1 or ABCG2 inhibition/knockdown in the absence of INH indicated function of 372" these proteins other than cellular efflux of drugs. Their recruitment to bacterial 373" phagosomes indeed point to such a possibility especially since their recruitment to the 374" phagosomes largely correlated with bacterial killing. ABC proteins are known to have 375" several moonlighting functions including nuclear translocation, redox balance and 376"
antigen presentation [53] [54] [55] [56] . Results suggest, at least in MSCs, they are also involved in 377"
bacterial killing in the phago-lysosomal system. Whether it is associated with 378" lysosomal acidification or transport of bactericidal effectors remains to be uncovered.
379"
It is however possible that ABC proteins are actively excluded from getting recruited 380"
to Mtb phagosomes while being present on other endo-lysosomal vesicles, where 381" through their inwardly transport activities sequester certain anti-bacterial effectors 382" including anti-TB drugs, away from mycobacterial phagosomes in isolated vesicles.
383"
This could potentially explain why knocking down or inhibition of ABCC1 or 384" ABCG2 helps increased bacterial survival. At present we have no evidence to support 385" whether these effectors could be H + ions, oxidized glutathione or glutathione metal 386" adducts, ubiquitin-derived peptides and other anti-microbial peptides; each of which 387" are capable of killing the bacteria and are also known targets of ABC proteins-388" mediated transport across biological membrane 53, 57 .
389"
Mycobacterial drug tolerance can also be induced in vitro or ex vivo in macrophages.
390"
In vitro, Mtb develops drug tolerance under stress conditions like hypoxia, NO, 391" nutrient stress etc. 7, 58 . There are also reports, which suggest mere macrophage 392" residence for few hours is sufficient to induce drug tolerance in Mtb 50 . Yet another 393" study reported increased bacterial drug tolerance in activated macrophages 35 . The 394" common thread across these studies is that when Mtb witnesses stress whether in vitro 395" or in vivo, it activates a set of genes which inadvertently also helps them tide-over the 396" effect of drugs 11, 35 . In agreement with the activated macrophage studies, we noted 397" further increase in drug tolerance of MSC-resident Mtb when activated by 398" inflammatory cytokines like IFNγ and TNFα. Most surprisingly though, in the 399" absence of drugs, IFNγ or TNFα treatment did not kill the bacteria, rather helped them 400" grow better. To our knowledge, this is the first report, where under any circumstance 401" a pro-bacterial role for these classic pro-inflammatory cytokines is reported. However although does not explain increased bacterial survival upon inflammatory stimuli.
411"
However similar to what we noted about ABCC1 or ABCG2 inhibition; pro-bacterial 412" effects of IFNγ and TNFα had mostly to do with lysosomal killing. Since each of 413" these treatments were for the final 24 hours before CFU plating were done, it cannot 414" reflect increased bacterial replication rather show diminished bacterial killing. This 415" observation however brings an exceptionally worrisome insight on the problem of 416" 
449"
Results from our experiments suggest, smart inclusion of COX2 inhibitors in standard 450" tuberculosis treatment/prevention regimens could enhance the efficacy of treatment.
451"
The two major hurdles in the tuberculosis control program are a) lack of effective 452" TNF-α were purchased from ebiosciences. siRNAs (ABCC1, ABCG2) were from GE 494" DHARMACON. Safranin O, Oil Red O and Alizarin Red S was purchased from SRL 495" chemicals.
496"
Cell culture 497"
Adipose tissue derived mesenchymal stem cells (ADSC) were purchased from life 498" technology (cat no -R7788115) and maintained in mesenPRO RS media (cat no 499" 12746012) supplemented with growth factors at 37°C, 5% CO2, humidified incubator 500" as per the manufacturer instructions and guidelines. For all in vitro experiments, 501" ADSC were seeded at the required density, allowed to adhere to the surface for 24-36 502" hours before proceeding with the experiment.
503"
Human monocytic cell line THP-1 were obtained from American type culture 504" collection (ATCC) and cultured in RPMI 1640 medium along with 10% fetal bovine 505" serum (FBS) at 37°C, 5% CO 2 humidified incubator. THP-1 derived macrophages 506"
(dTHP-1) were obtained by treating THP-1 cells with 20ng/ml phorbol myristate 507" acetate (PMA, sigma) for 24 hours followed by PMA removal and maintenance in 508" complete media." 509"
MSC Characterization
510"
MSC characterization into 3 lineages i.e. osteocytes, chondrocytes and adipocytes 511"
were done according to the differentiation protocol by life technologies. In brief, 512" MSC were seeded in 24 well plate and after 6-8 hours of adherence their media was 513" replaced with adipocyte differentiation media (cat no A1007001), chondrocyte 514" differentiation media (cat no A1007101) and osteocyte differentiation media (cat no 515" A1007201). Media was replaced every 3 rd day till 14 th day. After 14 days, cells were 516" fixed and stained with Alizarin red S for chondrocytes, Oil Red O for adipocytes, 517"
Safranin O for osteocytes.
518"
Bacterial cultures and in vitro infection experiments 519"
Virulent laboratory strain H37Rv and vaccine strain BCG bacterial cultures were 520" grown in 7H9 media (BD Difco) supplemented with 10% Albumin -Dextrose -521" Catalase (ADC, BD Difco) and incubated in an orbitary shaker at 100 rpm, 37° C 522" until the mid-log phase. Single cell suspension required for carrying out infection 523" experiments were prepared by passing bacterial culture through a series of different 524" gauge needles, five times through 23 gauge and 26 gauge and thrice through 30 525" gauge.
526"
For macrophage experiments, bacterial infection was set up for 4 hours followed by 527"
RPMI wash and addition of amikacin sulphate at a final concentration of 200µg/ml 528" for 2 hours to kill any extracellular bacteria. For ADSCs, infection was done for 12 529"
hours followed by addition of amikacin sulphate (200µg/ml) for 2 hours and 530" replenishment of fresh media. All the treatments of drug, cytokines, autophagy 531" modulators or chemical inhibitors were done 24 hours before the 6 th day and 3 rd day 532" time point for ADSC and dTHP-1 respectively while siRNA transfections were done 533" 48hrs before the 6 th day and 3 rd day time point for ADSC and dTHP-1 respectively.
534"
Bacterial colony forming units (CFU) were enumerated by adding lysis buffer, 7H9 535" containing 0.1% SDS in the required plate and incubating for 5 min and plating on 536"
7H11 agar plates supplemented with OADC (BD Difco). The plates were incubated at 537" 37°C to allow bacterial growth, and counts were performed after 21 days. Percent 538" tolerant population was calculated for CFU obtained in drug treated set as percent of 539" the CFU in the untreated set from the same experiment. 540"
MTT Assay
541"
Cell viability was assessed by performing MTT (sigma) [3-(4,5-dimethyl-2-thiazolyl)-542" 2,5-diphenyl-2H-tetrazolium bromide] assay. At indicated time points, media was 543"
removed from the plate and washed once with phenol free RMPI. MTT was prepared 544" in phenol free RPMI at a working concentration of 1 mg/ml. 100 µl of MTT solution 545" was added to each well of 96 well plates and incubated for appropriate time in cell 546"
incubator. Thereafter, MTT solution was removed and formazan crystals were 547" dissolved in 100 µl DMSO. Samples obtained thereafter were quantified by 548" measuring their absorbance at 560 nm in the plate reader. 549"
Confocal microscopy 550"
For confocal experiments, bacteria were stained with CellVue@claret dye (sigma) or 551" PKF67, far-red/green lipophilic dye, according to the manufactures protocol and 552" resuspended into final media and incubated with cells for infection. To visualize 553" acidified compartments, LysoTracker red dye (LysoTracker Red DND-99; Life 554" Technologies) was added to the sample wells at a concentration of 500 nM for 30 555" mins. Cells were fixed in 4% (w/v) PFA for 15-20 mins, followed by PBS wash twice 556" and ammonium chloride treatment for 15 mins. Cells were again washed with PBS 557" and incubated with 0.2 % TritonX-100 in 1X PBS for 20 min to ensure 558" permeabilization. It was followed by blocking solution (3% BSA in 1X PBST) for 1 559" hour. Cells were then incubated with primary antibody for 2-3 hours at RT, followed 560"
by PBST wash and conjugated secondary antibody for an hour. Cells were given a 561"
final wash with 1X PBS and coverslips were mounted in ProLong Gold antifade 562" reagent (Life Technologies). Images were acquired by NIS-Elements software using 563" the Nikon A1R laser scanning confocal microscope equipped with a Nikon Plan Apo 564" 60× 1.40-numerical-aperture (NA) oil immersion objective. Serial confocal sections, 565" 0.5 µm thick, were acquired within a z-stack spanning 10 to 15 µm to form a 566" composite image. Images were analysed using Imaris and image J software 567" 568"
Flow cytometry 569"
Surface and intracellular protein expression in THP-1 and ADSC were carried out 570" using flow cytometry. At required time points, cells were scrapped off, pelleted and 571"
washed. Cells were pelleted down at 1000 rpm and blocked in 3% BSA in 1X PBS 572"
and incubated with primary antibody for 3 hr in blocking buffer followed by 573" incubation with alexa flour 488 conjugated secondary antibody for 2 hrs (surface 574" expression). Intracellular expression was assessed after permeabilizing cells with 575" 0.05% saponin, followed by blocking, primary and secondary antibody incubation.
576"
After incubations cells were washed with 1X PBS and re-suspended in 1X PBS and 577" samples were acquired in BD FACS Canto II by using FACS Diva acquisition 578"
software. For measurement of cellular ROS, cells were scrapped at required time 579" point and stained with CellROX Green before acquisition on BD FACS Canto II.
580"
Staining of the dyes were performed as per the manufacturer's directions. The data 581" was analyzed using Flow Jo V. software.
582"
Real time PCR and Microarray
583"
Total RNA from ADSC and dTHP-1 cells was isolated using mdi RNA isolation kit.
584"
cDNA was synthesized from 500ng of total RNA by reverse transcriptase PCR using 585" Bio-RAD iScript cDNA synthesis kit according to the manufacturer's protocol.
586"
ADSC and dTHP-1 cDNA samples was run in triplicate using β-tubulin and actin as 587" normalizing control respectively using SYBR green dye for real time fluorescence 
596"
For microarray, total RNA from ADSC uninfected or infected H37Rv was extracted 597" using MDI RNA isolation kit. Samples were sent to Bionivid Technologies, 598" Bangalore for cDNA synthesis and hybridization to 25 "Illumina human 599" WholeGenome-6 version 2 BeadChips" using standard illumina protocols. Six 600" biological replicates were used for hybridization. 601" C57BL/6 aerosol challenge 602"
All mice experiments were carried out in the Tuberculosis Aerosol Challenge Facility 603" (TACF, ICGEB, New Delhi, India). C56BL/6 mice were housed in cages contained 604" within a biosafety level 3 laminar flow enclosure. Aerosol challenge of 100 CFU was 605"
given to the animals in a Wisconsin-Madison chamber according to the standardized 606"
protocol. To check for infection establishment, two animals were selected randomly 607"
and humanely euthanized 24 hours post-aerosol challenge. The lungs and spleen 608" tissues were harvested and homogenized to enumerate CFU. Tissue lysates were 609" serially diluted and plated on petri plates containing Middlebrook 7H11 agar (Difco) 610" supplemented with 10% OADC (Becton, Dickinson) and 0.5% glycerol.
611"
Animal dosing, CFU plating and FACS sorting 612"
For in vivo experiments, drug dosing was initiated 4 weeks post-aerosol challenge and 613" the animals were administered the drug by oral gavage at a dose of 10 mg/kg INH and 614" 50 mg/kg celecoxib in combination and individually every day till 12 weeks. After 8 615"
and 12 weeks, 6 mice in each group were euthanized, followed by removal of lung 616" and spleen and their homogenization and plating. Half lung was used in the 617" preparation of single cell suspension followed by FACS sorting and subsequent 618"
plating. To begin with the tissue was washed with PBS, chopping it in small pieces 619" followed by addition of 20U/ml DNAses, 1mg/ml collagenase D and incubation for 620" 30 mins at 37C. This is passed through nylon mesh to get single cell suspension. The 621" cells were pelleted at 2000 rpm, treated with RBC lysis buffer, washed with PBS.
622"
Cells were stained with the antibody cocktail of CD45, CD73, CD11b, ly6G, sca-1 623"
and just before sorting PI were added at 5µg/ml for live/dead staining. All the cells 624"
were sorted to get the maximum number of sorted cells which were then pelleted, 625" lysed and plated.
626"
Immunohistochemistry
627"
Five-micron thick sections of tissue were taken on the coated slide. Deparaffinization 628" was done by dipping the slides in xylene for 5 mins (2 changes), acetone for 2-3 mins, 629" alcohol for 2-3 mins and then under running/tap water. Antigen retrieval was 630" performed with citrate buffer (pH=6) in microwave oven, at 100 o C for 30 minutes.
631"
Endogenous persxidase blocking was done with 4% Hydrogen peroxide in methanol.
632"
Rabbit anti-Ag85B primary antibody was added (1:400) and incubated overnight.
633"
Thereafter goat anti-rabbit IgG H&L (ab6721) was added and incubated for 40 634" minutes followed by 200 µl of enhancer for 5 minutes at RT. For color development, 635" 3-amino-9-ethiylcarbazole chromogen was used at RT for 15 minutes. Thereafter the 636"
Mouse anti-CD73 antibody (ab91086, abcam, Cambridge, USA) was added in a 637" dilution of 1:500 overnight at RT. Alkaline phosphatase tagged goat anti-mouse IgG 638" H&L secondary antibody (ab7069) was added (1:200) for 40 minutes at room 639" temperature. Color was developed using a Stay Green/ AP plus kit (ab156428) 640" following manufacturer's protocol.
641"
Statistical analysis 642"
Statistical significance for comparisons between two sets of the experiments was done 643" using unpaired two-tailed Students's t-test. **denotes significant difference at P<0.01 644" and * at P<0.05. 645"
